Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer

European Journal of Cancer

Volumn 43, Issue 16, 2007, Pages 2345-2350

  de Jong, Wouter K ^a   Groen, Harry J M ^a   Koolen, Mia G J ^b   Biesma, Bonne ^c   Willems, Luuk N A ^d   Kwa, Hian Bie ^e   van Bochove, Aart ^f   van Tinteren, Harm ^g   Smit, Egbert F ^h  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^f ZAANS MEDICAL CENTER   (Netherlands)

^g Integraal Kankercentrum Amsterdam   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Extensive disease; Phase III study; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER FATIGUE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 35448929533     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.029     Document Type: Article

References (21)

1. Postmus P.E., Scagliotti G., Groen H.J., et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer 32A (1996) 1498-1503
2. Ardizzoni A., Tjan-Heijnen V.C., Postmus P.E., et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 20 (2002) 3947-3955
3. Giaccone G., Dalesio O., McVie G.J., et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11 (1993) 1230-1240
4. Tjan-Heijnen V.C., Postmus P.E., Ardizzoni A., et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12 (2001) 1359-1368
5. Chute J.P., Chen T., Feigal E., Simon R., and Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17 (1999) 1794-1801
6. Roth B.J., Johnson D.H., Einhorn L.H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10 (1992) 282-291
7. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
8. Hanna N., Bunn Jr. P.A., Langer C., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038-2043
9. Eckardt J.R., von Pawel J., Papai Z., et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24 (2006) 2044-2051
10. Socinski M.A., Weissman C., Hart L.L., et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24 (2006) 4840-4847
11. Groen H.J., Fokkema E., Biesma B., et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 17 (1999) 927-932
12. Thomas P., Castelnau O., Paillotin D., et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 19 (2001) 1320-1325
13. Gridelli C., Manzione L., Perrone F., et al. Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. Br J Cancer 84 (2001) 38-41
14. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
15. Pocock S.J., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975) 103-115
16. Sundstrom S., Bremnes R.M., Kaasa S., et al. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48 (2005) 251-261
17. Urban T., Chastang C., Lebas F.X., et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small-cell lung carcinoma: a randomized study of 457 patients. Petites Cellules Group Cancer 86 (1999) 2238-2245
18. Deppermann K.M., Serke M., Oehm C., et al. Paclitaxel and carboplatin in advanced SCLC: a phase II study. Proc Am Soc Clin Oncol 18 (1999) 482a
19. Timmer-Bonte J.N., de Boo T.M., Smit H.J., et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23 (2005) 7974-7984
20. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
21. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453